Abstract:Programmed death-ligand 1 (PD-L1) plays an important role in T cell tolerance and tumor immune escape, which has been reported to be a prognostic factor in various malignancies. However, only a few studies about PD-L1 in nasopharyngeal carcinoma (NPC) are available, and the reported prognostic role of PD-L1 in NPC patients remains controversial. In this study, we aimed to investigate the alterations of PD-L1 expression on tumor cells in NPC patients with and without metastasis. Furthermore, we would explore the correlation of PD-L1 expression on tumor cells and serum Epstein-Barr virus (EBV) DNA load. Pathologically confirmed NPC treated with intensity-modulated radiation therapy were recruited for the study. Formalin-fixed, paraffin-embedded tissues were studied by immunohistochemistry staining. The expression of PD-L1 on tumor cells was detected and the staining results were evaluated by positive tumor cell percentage. Clinical characteristics and qRT-PCR data of serum EBV DNA load before treatment were collected. The optimal cut-off value for PD-L1 staining was determined by the area under the curve of the receiver operating characteristic (ROC). The Chi-square test was used to evaluate results with SPSS 25.0. A total of 78 patients were included in this study, with median follow up 52.8 months (range 12-108 months). The median age was 44 years old (range 22 –65 years). Among those 78 patients, 43(55%) patients had metastasis, 35 (45%) did not have metastasis. PD-L1 expression on tumor cells was detected in 66 patients (66/78, 85%). When staining with PD-L1 on >45% tumor cells, PD-L1 expression was classified as being at a high level according to the ROC curve analysis. In metastasis group, 25 out of 43 patients showed high PD-L1 expression, while in non-metastasis group only 7 out of 35 patients showed high PD-L1 expression (p=0.001). We observed that more patients in metastasis group had detectable serum EBV DNA load than non-metastasis group (p=0.007). In order to study the effect of EBV on PD-L1 expression, we explored the correlation of PD-L1 expression on tumor cells and serum EBV DNA status (before treatment). Our data showed that PD-L1 expression was not significantly correlated with EBV DNA load among all the patients (p= 0.554). Our results revealed that PD-L1 might be a potential metastatic biomarker for NPC patients. Furthermore, EBV status was not significantly correlated with PD-L1 expression. PD-1/PD-L1 pathway might be a promising therapy target for advanced NPC.

Effect of PD-L1 and tumor regression rate on prognosis of nasopharyngeal carcinoma

Clinical significance of the expression of programmed death-1 in nasopharyngeal carcinoma

High PD-L1 Expression Predicts Metastasis in Nasopharyngeal Carcinoma

Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes.

Expression of programmed death ligand-1 predicts poor outcome in nasopharyngeal carcinoma

Anti-PD-(L)1-Based Neoadjuvant Therapy in Head and Neck Carcinoma: a Meta-analysis of Prospective Clinical Trials.

Correlation of PD-L1 Expression of Tumor Cells with Survival Outcomes after Radical Intensity-Modulated Radiation Therapy for Non-Metastatic Nasopharyngeal Carcinoma

PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy

Good prognostic factor in patients with nonmetastatic nasopharyngeal carcinoma: Programmed death ligand-1 expression in tumor cells

Co-expression of PD-1 and PD-L1 Predicts Poor Outcome in Nasopharyngeal Carcinoma

PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes

Association of Lymphocyte Subsets Percentage with Prognosis for Recurrent or Metastatic Nasopharyngeal Carcinoma Patients Receiving PD-L1 Inhibitors

PD-L1 expression as a potential predictor of immune checkpoint inhibitor efficacy and survival in patients with recurrent or metastatic nasopharyngeal cancer: a systematic review and meta-analysis of prospective trials

The Prognostic Significance of PD-L1 and PD-1 Expression in Patients with Nasopharyngeal Carcinoma: a Systematic Review and Meta-Analysis.

PD-1 High Expression Predicts Lower Local Disease Control in Stage IV M0 Nasopharyngeal Carcinoma

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Nasopharyngeal Carcinoma: A Meta-Analysis of 1,315 Patients

PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial

Prognostic Analysis of Patients with Locally Advanced Nasopharyngeal Carcinoma Following Intensity Modulated Radiation Therapy.

The clinical prognostic value of PD-L1 after concurrent chemoradiotherapy in Chinese nasopharyngeal carcinoma patients

Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer